
Industry Webinar: A New Dawn for IgA Nephropathy – Redefining What is Possible With Sparsentan
-
Register
- Non-member - Free!
- Member - Free!
- Subscriber - Free!
- Free trial - Free!
KDIGO draft guidelines recommend that proteinuria, the only validated biomarker for disease progression in IgAN, be maintained at <0.5 g/d (preferably <0.3 g/d) to reduce the rate of kidney function loss to <1 ml/min/y. In the PROTECT phase 3 study, sparsentan reduced proteinuria and increased the proportion of pts achieving proteinuria of <0.5 or <0.3 g/d. Post-hoc analyses showed that achieving low proteinuria was predictive of better long-term kidney function, and pts once considered low risk (UPCR < 1.0 g/g) also benefited from these proteinuria reductions. Similar proteinuria reductions were observed in treatment naïve pts in the interim analyses of the phase 2 SPARTAN trial. As nephrologists consider the evolving treatment landscape and guidance, foundational nephroprotective therapies will be key to reducing proteinuria and preserving kidney function.
Learning objectives:
- Describe the draft KDIGO criteria for risk of disease progression in IgAN, the proposed target proteinuria levels for preserving kidney function, and the scientific rationale for these proposed proteinuria targets
- Describe the clinical benefits of achieving proteinuria remission and how sparsentan helps clinicians achieve these targets
- Evaluate the evolving IgAN therapeutic landscape and where sparsentan fits into treatment in order to achieve proteinuria remission and reduce nephron loss
Further reading:
- Rovin BH, et al. Lancet. 2023;402(10417):2077-2090. (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02302-4/abstract)
- Pitcher D, et al. Clin J Am Soc Nephrol. 2023;18(6):727-738 https://journals.lww.com/cjasn/fulltext/2023/06000/long_term_outcomes_in_iga_nephropathy.9.aspx
- PROTECT post-hoc proteinuria remission analyses

Sydney Tang
Hong Kong
